FDA
-
-
-
-
-
-
-
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
-
-
-
-
-
-
-
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
H.C. Wainwright Starts Sagimet Biosciences Inc (SGMT) at Buy
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

